How Michael Hall’s TOR Discovery Reframed Longevity Science
Send us a textWe trace how a soil-derived drug led to the discovery of mTOR, why growth control sits at the core of aging biology, and where evidence ends for humans. Michael Hall’s quiet breakthroughs explain fasting, autophagy, and rapamycin without the hype.To read more about this topic and for more science stories, visit our website swisinfo.ch. You can help other people to find our podcast by leaving us a five-star review.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern, Switzerland.
--------
18:21
--------
18:21
Big Pharma steps up race for AI-discovered drugs
Send us a textWhat if the most valuable drug candidates aren’t found but designed on demand? We follow a chemist’s journey from a pencil-and-paper notebook to generative algorithms that propose novel, IP-free molecules tailored to specific targets, and we open the door to how Swiss pharma is rebuilding discovery around AI.To read more about this topic and for more science stories, visit our website swisinfo.ch. You can help other people to find our podcast by leaving us a five-star review.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern, Switzerland.
--------
16:16
--------
16:16
Women’s Health Meets Drug Design and Medical Research
Send us a textWe trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern, Switzerland.
--------
18:28
--------
18:28
Cracking the Alzheimer’s Code
Send us a textAlzheimer’s disease is more than age-related memory loss—it’s a serious brain disorder. In this episode of the Swiss Connection Science podcast, Swissinfo healthcare reporter Jessica Davis Pluess explores the science, hope, and controversy surrounding new Alzheimer’s drugs like Leqembi and Kisunla. With billions invested and global regulatory decisions diverging, what do these treatments mean for patients and healthcare systems? Visit SWI swissinfo.ch for more on this topic and a video on this story. Please come to SWI swissinfo.ch for more of our science stories from Switzerland.Journalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern, Switzerland.
--------
21:12
--------
21:12
Swiss Longevity clinics: modern-day snake oil or the key to healthy ageing?
Send us a textThe search for the elixir of life has been going on since time immemorial – and Switzerland has played a key role. Although scientists have yet to come up with a winning formula, the Alpine nation has a booming market for treatments, pills and gadgets that claim to slow ageing and help us live healthier, longer lives.Visit SWI swissinfo.ch for more on this topic and a video on this story. Please come to SWI swissinfo.ch for more of our science stories from Switzerland.Jounalist: Jessica Davis PlüssHost: Jo FahyAudio editor/video journalist: Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern, Switzerland.
Discover science and innovation in Switzerland with the Swiss Connection Podcast! From the tiniest particles to the vastness of space, satisfy your scientific curiosity and join our journalists while they talk to researchers working on projects ranging from rocket building and AI to medicine and climate solutions. This podcast is produced by SWI swissinfo.ch, a multilingual public service media company in Switzerland.
USA